Ph1 CPX-351 combined with various agents in previously untreated AML - Clinical Trial
What is the Purpose of this Study?
We are doing this study to learn more about how safe and effective it is for patients with newly diagnosed AML to take the study drug, CPX-351 given in combination with venetoclax, midostaurin or enasidenib.
Patients with Previously Untreated Acute Myeloid Leukemia (AML)
Who Can Participate in the Study?
Adults with newly diagnosed AML who:
- Do not have acute promyelocytic leukemia
- Have not received prior treatment intended for induction therapy of AML
- Are not receiving any therapy for MDS
What is Involved?
If you choose to join this study, you will:
-Take the study drug (CPX-351) by infusion (into the vein) at the clinic
-Have blood drawn
-Have a physical exam
-You will participate in the study anywhere from 42-224 days, depending on how much you need